Global Information
회사소개 | 문의 | 위시리스트

당뇨병 진단과 모니터링 시장 : 이그제큐티브 및 컨설턴트 가이드, 맞춤형 예측과 분석(2020-2024년)

Diabetes Diagnostic & Monitoring Markets with Executive and Consultant Guides. Including Customized Forecasting and Analysis 2020 to 2024

리서치사 Howe Sound Research
발행일 2019년 06월 상품 코드 855451
페이지 정보 영문 228 Pages
가격
US $ 5,995 ₩ 7,208,000 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 8,995 ₩ 10,816,000 PDF by E-mail (Five User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 5대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 11,995 ₩ 14,423,000 PDF by E-mail (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



당뇨병 진단과 모니터링 시장 : 이그제큐티브 및 컨설턴트 가이드, 맞춤형 예측과 분석(2020-2024년) Diabetes Diagnostic & Monitoring Markets with Executive and Consultant Guides. Including Customized Forecasting and Analysis 2020 to 2024
발행일 : 2019년 06월 페이지 정보 : 영문 228 Pages

세계의 당뇨병 진단과 모니터링(Diabetes Diagnostic & Monitoring) 시장에 대해 조사했으며, 시장 현황과 향후 동향, 성장 기회, 지역별 동향, 시장 참여 기업의 개요에 대해 정리하여 전해드립니다.

제1장 시장 가이드

  • 개요
  • 당뇨병 이환율
  • 시장의 정의
  • 조사 방법
  • 미국 시장

제2장 질환의 이해

  • 1형 당뇨병
  • 2형 당뇨병
  • 당뇨병 관련 질환
    • 심혈관
    • 신장
    • 신경병증
    • 안질환/실명
    • 뇌경색·치매
    • 성기능 부전/임신
    • 감염과 기타
    • 당뇨병케톤산증
  • 췌장과 자가면역

제3장 업계 개요

제4장 시장 동향

  • 성장 촉진요인
  • 성장 저해요인
  • 진단 기술 개발

제5장 최근 발전

제6장 주요 기업 개요

제7장 시장 동향

  • 국가별 시장 개요

제8장 어세이별 시장

  • 개요
  • 혈당치 어세이
  • HbA1c 어세이
  • 혈당 모니터링

부록

KSA 19.06.12

Table of Tables

  • Table 1: Diabetes Prevalence by Region
  • Table 2: Lab Spending 2014 to 2024
  • Table 3: Market Players by Type
  • Table 4: Five Factors Driving Growth
  • Table 5: Three Factors Limiting Growth
  • TABLE 6: - GLOBAL DIABETES DIAGNOSTICS MARKET BY REGION
  • TABLE 7: GLOBAL MARKET BY ASSAY
  • TABLE 8: DIABETES DIAGNOSTICS GLUCOSE BY COUNTRY
  • TABLE 9: DIABETES DIAGNOSTICS GLUCOSE BY LAB, POC HOSPITAL, POC CONSUMER
  • TABLE 10: DIABETES DIAGNOSTICS HBA1C BY COUNTRY
  • TABLE 11: DIABETES DIAGNOSTICS HBA1C BY LAB, POC HOSPITAL, POC CONSUMER
  • TABLE 12: DIABETES DIAGNOSTICS CONTINUOUS GLUCOSE MONITORING BY COUNTRY
  • Table 13: 2018 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Diabetes Global Prevalence Map
  • Figure 2: Prevalence by income Group and Age
  • Figure 3: Undiagnosed Cases by Region
  • Figure 4: Reasons for Increasing Prevalence
  • Figure 5: Clinical Lab Spending 2014 to 2024
  • Figure 6: Obesity Prevalence Map of USA
  • Figure 7: Growth in Health Care Spending Developing World
  • Figure 8: Comparing The New Diagnostics and Traditional Testing
  • Figure 9: Growth rates of Diabetes Diagnostics
  • Figure 10: 2018 Global Market Density Chart
  • Figure 11: DIABETES DIAGNOSTICS Market by Assay - 2019 vs. 2024
  • FIGURE 12: DIABETES DIAGNOSTICS MARKET 2019
  • FIGURE 13: DIABETES DIAGNOSTICS MARKET 2024
  • FIGURE 14: ASSAY SHARE BY YEAR
  • FIGURE 15: DIABETES DIAGNOSTICS HBA1C GROWTH
  • FIGURE 16: DIABETES DIAGNOSTICS GLUCOSE GROWTH
  • FIGURE 17: DIABETES DIAGNOSTICS HBA1C GROWTH
  • FIGURE 18: DIABETES DIAGNOSTICS HBA1C GROWTH
  • FIGURE 19: DIABETES DIAGNOSTICS CONTINUOUS GLUCOSE MONITORING TESTING GROWTH

OVERVIEW:

Will diabetes management become a diabetes cure? Diabetes management is moving onto phones and laptops and integrated into physicians' databases. Well established players are jockeying for position in this emerging digital environment while the fundamentals suggest global growth that will continue well into the future. The results of these efforts will change what diabetes means to millions of people worldwide. The digital revolution is breathing new life into the commodity world of testing strips. Understand what is driving this huge global diagnostic market.

Our facts and support = Your success.

The report forecasts the market size out to 2024. Growth is coming from the fundamentals and the move to real time data management of blood parameters. When does effective management constitute a cure? New technologies are bringing an artificial pancreas into view. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Digital Diagnostics are merging with spectacular success.

Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to a wider license. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Market Guides

  • iA. Situation Analysis
  • iB. Guide for Executives and Marketing Staff
  • iC. Guide for Investment Analysts and Management Consultants

1. Introduction and Market Definition

  • 1.1. An Overview of Diagnostics and Monitoring of Diabetes
  • 1.2. Diabetes Prevalence - the Big Picture
    • Table: Diabetes Prevalence by Region
    • Figure: Diabetes Global Prevalence Map
    • Figure: Prevalence by Income Group and Age
    • 1.2.1. Undiagnosed Diabetes - The Opportunity
      • Figure: Undiagnosed Cases by Region
    • 1.2.2. Prevalence Increasing - the Drivers and the Implications
      • Figure: Reasons for Increasing Prevalence
  • 1.3. Market Definition
    • 1.3.1. Market Size
    • 1.3.2. Currency
    • 1.3.3. Years
    • 1.3.4. Glucose Assay
    • 1.3.5. HbA1c Assay
    • 1.3.6. Continuous Glucose Monitoring
    • 1.3.7. Laboratory Assay
    • 1.3.8. Point of Care Hospital
    • 1.3.9. Point of Care Consumer
  • 1.4. Methodology
    • 1.4.1. Authors
    • 1.4.2. Sources
  • 1.5. U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1. U.S. Medicare Expenditures for Laboratory Testing Diabetes - Current Science

2.0. Understanding the Disease

  • 2.1. Type 1
    • 2.1.1. Causes
    • 2.1.2. Diagnosis
  • 2.2. Type 2
    • 2.2.1. Causes
    • 2.2.2. Diagnosis
  • 2.3. Diabetes Related Disease
    • 2.3.1. Cardiovascular
    • 2.3.2. Renal
    • 2.3.3. Neuropathy
    • 2.3.4. Eye Damage/Vision Loss
    • 2.3.5. Stroke and Dementia
    • 2.3.6. Sexual dysfunction/pregnancy
    • 2.3.7. Infection and Other
    • 2.3.8. Diabetic Ketoacidosis
  • 2.4. Pancreas and Autoimmunity
    • 2.4.1.R ole of Pancreas
    • 2.4.2. Autoimmunity

3. Industry Overview

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Academic Research Lab
    • 3.1.2. Diagnostic Test Developer
    • 3.1.3. Pharmaceutical/Reagent Supplier
    • 3.1.4. Independent Testing Lab
    • 3.1.6. Public National/regional lab
    • 3.1.7. Hospital lab
    • 3.1.8. Physician Lab
    • 3.1.9. Audit Body
    • 3.1.10. Certification Body

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Increasing Prevalence
    • 4.1.2. Obesity Epidemic
    • 4.1.3. Rapid Low Cost Diagnositics
    • 4.1.4. Wellness and Health Management
    • 4.1.5. Move to Point of Care
    • 4.1.6. Developing World Health Care Spending
  • 4.2. Factors Limiting Growth
    • 4.2.1. The Cost Curve Shrinks the Market
    • 4.2.2. The Diagnostics Dillemma
    • 4.2.3. Systemic Roadblocks
  • 4.3. Diagnostic Technology Development
    • 4.3.1. The Screening Opportunity
    • 4.3.2. Shifting Role of Physicians in Diagnosis
    • 4.3.3. Diagnostics Moves Out of the Lab
    • 4.3.4. The Diabetes Management Apps
    • 4.3.5. From Monitor to Pumps - Strategic Partnership Plays
    • 4.3.6. The Next Five Years

5. Diabetes Diagnostics - Recent Developments

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
      • Diabetes app Glucose Buddy supports Dexcom CGM devices
      • ABBOTT'S FREESTYLE® LIBRE 2 SECURES CE MARK
      • Siemens Healthineers and Hill-Rom to Provide Comprehensive Diabetes Care
      • Trividia Health, Inc. to acquire Freedom Meditech
      • Medtronic to Acquire Nutrino Health
      • Nova Biomedical Receives FDA Clearance for Capillary Testing with Critically Ill Patients
      • ARKRAY announces new blood glucose monitoring systems.
      • Life365 Extends Connected Care Platform Partnership with OSANG Healthcare
      • AgaMatrix Enters Strategic Partnership with Arcadia Group
      • PTS Diagnostics Updated System, Lowers Average Cost Per Test
      • ACON Laboratories Launches New System for the Veterinary Market
      • Senseonics extends distribution agreement with Roche Diabetes Care
      • Ascensia Diabetes Care Announces Global Partnership with Poctech
      • New Release of OneTouch Reveal® Mobile App
      • J&J to sell Lifescan, dropping out of diabetes diagnostics

6. Profiles of Key Companies

  • A.Menarini Diagnostics Ltd.
  • Acon Laboratories, Inc.
  • AgaMatrix, Inc.
  • Agilent (Dako)
  • Apex Biotechnology Corporation
  • ARKRAY, Inc.
  • Ascensia Diabetes Care Holdings AG
  • B. Braun Melsungen AG
  • Becton, Dickinson & Co.
  • Beckman Coulter, Inc.
  • BIONIME Corporation
  • Bio-Rad Laboratories
  • Danaher Corporation
  • DexCom, Inc.
  • Diazyme Laboratories Inc.
  • EKF Diagnostics Holdings Plc
  • HemoCue® AB
  • LifeScan, Inc.
  • Medtronic PLC
  • Nipro Europe
  • Nova Biomedical Corporation
  • OSANG Healthcare Co., Ltd.
  • Pepex Biomedical
  • PTS Diagnostics
  • Roche Diabetes Care, Inc.
  • Sanofi S.A.
  • Sanwa Kagaku Kenkyusho Co, Ltd.
  • Siemens Healthineers
  • Sinocare, Inc.
  • Trividia Health, Inc.
  • TaiDoc Technology Corporation
  • Tandem Diabetes Care, Inc.
  • Terumo Corporation
  • Thermo Fisher Scientific
  • Tosoh Bioscience, Inc.
  • Trinity Biotech plc
  • Ypsomed AG

7. Diabetes Diagnostic Markets

  • 7.1. DIABETES DIAGNOSTICS - Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country

8. Global DIABETES DIAGNOSTICS Markets - By Assay

  • 8.1. Global Market by Assay - Overview
    • 8.1.1. Table - Global Market by Assay
    • 8.1.2. Chart - Global Market by Assay - 2019/2024 Comparison
    • 8.1.3. Chart - Global Market by Assay - 2019
    • 8.1.4. Chart - Global Market by Assay -2024
    • 8.1.4. Chart - Global Market by Assay - Share by Year
  • 8.2. DIABETES DIAGNOSTICS Glucose Assay
    • 8.2.1. Table DIABETES DIAGNOSTICS Glucose - by Country
    • 8.2.2. Chart - DIABETES DIAGNOSTICS Glucose Growth
    • 8.2.3. Table DIABETES DIAGNOSTICS Glucose by Lab, PoC Hospital, PoC Consumer
    • 8.2.4. Chart - DIABETES DIAGNOSTICS Glucose Growth by Lab, PoC Hospital, PoC Consumer
  • 8.3. DIABETES DIAGNOSTICS HbA1c Assay
    • 8.3.1. Table DIABETES DIAGNOSTICS HbA1c- by Country
    • 8.3.2. Chart - DIABETES DIAGNOSTICS HbA1c Growth
    • 8.3.3. Table DIABETES DIAGNOSTICS HbA1c by Lab, PoC Hospital, PoC Consumer
    • 8.3.4. Chart - DIABETES DIAGNOSTICS HbA1c Growth by Lab, PoC Hospital, PoC Consumer
  • 8.4. DIABETES DIAGNOSTICS Continuous Glucose Monitoring
    • 8.4.1. Table DIABETES DIAGNOSTICS Continuous Glucose Monitoring - by Country
    • 8.4.2. Chart - DIABETES DIAGNOSTICS Continuous Glucose Monitoring Testing Growth

Appendices

  • I. United States Medicare System: 2018 Clinical Laboratory Fees Schedule - National Limit and Midpoint
Back to Top
전화 문의
F A Q